key: cord-0830133-wn1kiqmm authors: Foss-Solbrekk, Katarina title: The IP waiver and COVID-19: reasons for unwavering support date: 2021-12-11 journal: Journal of Intellectual Property Law & Practice DOI: 10.1093/jiplp/jpab150 sha: e681390899878626c6375098272267c240a16ad1 doc_id: 830133 cord_uid: wn1kiqmm nan • Compulsory licencing is not a satisfactory solution to vaccine inequality because it is a drugspecific and country-specific process, with legal and administrative complexities for developing countries. • An IP waiver, however, would allow developing and least developed countries to have better access to COVID-19 vaccines. Although several hurdles must first be overcome, including tech transfers, data disclosures, investments in production capabilities and an end to exports on raw materials, these are not insurmountable. In addition, because of the unprecedented amounts of public funding allocated throughout the vaccines' development cycle, a waiver would not harm innovation in the short term or medium term by removing incentives to develop essential pharmaceutical products. which will 'use up roughly 440 million doses of the global supply' . 5 Many developed countries see COVAX as a convenient solution. COVAX is run by the WHO, Gavi and the Coalition for Epidemic Preparedness and Innovations (CEPI); via donations of funds and vaccines from developed countries, the organization aims to ensure that developing countries have equitable access to COVID-19 tools. 6 But COVAX has experienced limited success. 7 Despite lofty targets of 2 billion doses to be shipped by end 2021, currently only 150 million doses have reached those countries most in need. 8 Vaccine nationalism remains a hindrance. India suspended exports on vaccines meant for COVAX amid its own COVID crisis in April-May 2021. 9 High-income countries such Canada even availed itself of dosages secured because of its participation in COVAX. 10 Moreover, as Katz confirms: 'Wealthier countries did bilateral deals with companies like Pfizer and Moderna to lock up contracts' , while there was also a 'lack of initial investment to COVAX' , meaning it was 'already too late' by the time COVAX received funds to order vaccines. 11 Purchasing fuel to transport vaccine doses to clinics, training vaccine administrators and persuading people to get vaccinated in developing countries are also cited as factors that have affected COVAX's impact. 12 Resolving these issues is vital to ensure that vaccines are properly distributed once produced. Against this background, it is understandable why developing countries should have the possibility to produce their own COVID-19 vaccines. Despite certain production ability concerns, it should be noted 6 WHO, 'COVAX: Working for Global Equitable Access to Vaccines' Available at https://www.who.int/initiatives/act-accele rator/covax ( that vaccine manufacturers in developing countries currently supply over 50 per cent of the vaccines used in immunization programmes in developing countries, 13 allowing for lower prices and with economies of scale and scope. Compulsory licencing is touted as one pathway for vaccine autonomy. However, compulsory licencing under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is poorly understood by many developing countries, is rarely used and has serious administrative drawbacks, requiring governmental implementation by each country for each drug. In addition, the WHO Technology AccessPool that was designed to address COVID-19 medical tools access problems is currently unused. Adopting the COVID-19 intellectual property (IP) waiver would represent a better route to equal vaccine accessibility and allow drug companies, scientific institutions and relevant government bodies to act immediately, without having to wait for state IP licencing. India and South Africa submitted a proposal to the World Trade Organization (WTO) on 2 October 2020 to waive intellectual property rights (IPRs) for COVID-19 products 14 under TRIPs. 15 Said waiver would allow WTO member countries to circumvent patent, copyright, industrial design and undisclosed information rights normally afforded to products targeting COVID-19. According to the proposal, the waiver would ensure that IPRs 'do not create barriers to the timely access to affordable medical products including vaccines and medicines or to scalingup of research, development, manufacturing and supply of medical products essential to combat COVID-19' . 16 Over 100 countries formally support the waiver, and a global petition signed by more than 900 000 people was submitted to the WTO in December 2020, asking governments, pharmaceutical companies and WTO members to 13 ensure universal access to COVID-19 treatments. 17 The USA now supports the IP waiver for COVID-19 vaccines, as does the European Parliament. High-income WTO members such as Germany, the UK, Norway and the EU, however, remain opposed and have thus far blocked the proposal during numerous TRIPs Council meetings, the most recent being in late July 2021, so little progress has been made. This article supports the calls for an IP waiver on all COVID-19 tools. This is especially crucial for vaccines, the most important measure to combat the pandemic. Although several hurdles must be overcome for the waiver to take effect, including tech transfers, data disclosures, investments in production capabilities and an end to exports on raw materials, these are not insurmountable problems. All in all, the article demonstrates that a waiver would help enable greater access to COVID-19 vaccines in developing and least developed countries. However, action must be taken quickly. Discussions of the waiver reveal two completely opposite interpretations of the role IPRs play in this pandemic. On the one hand, WTO members supporting the proposal stress that IPRs stand in the way of scaling up vaccine production and that the flexibilities offered under TRIPs, such as import-export compulsory licenses, are too cumbersome to be relied upon as a means of enabling access. 18 Opposing WTO members, on the other hand, claim that IPRs are a small and insignificant element impacting vaccine production and allocation. 19 Indeed, although adopting the waiver would allow third parties to use COVID-19 IP without fear of being sued, it would not automatically help scale up production and address vaccine inaccessibility in developing countries. If it did, then additional companies would perhaps already be producing Moderna's vaccine, given that Moderna has already publicly announced that it will not be enforcing its patents for 'COVID-19 related patents against those making vaccines intended to combat the pandemic' . 20 There are thus additional barriers to consider, namely, technology transfers, data disclosures, production capabilities and sourcing the raw materials needed to produce vaccines. It will be shown that these may be overcome, but first it is important to address why the waiver is needed when pre-existing TRIPs flexibilities exist, such as compulsory licences, and why such licences should not be relied upon as the first line of action to enable greater access to COVID-19 vaccines. A. Why waive if you 'can' licence? Indeed, an important legal question is why IP needs to be waived in the first place, given that countries already have the right to waive the vaccines' IPR and manufacture generic alternatives under the compulsory licences route under Article 31 of TRIPs, allowing domestic production. As Thambisetty et al. observe, 'a common argument which has been raised in opposition to the waiver proposal has been to suggest that the WTO system already allows for compulsory licensing so there is no need for a waiver' . 21 As an example, in the position statement 'Covid-19 and the Role of Intellectual Property' , by the Max Planck Institute for Innovation and Competition, Hilty et al. claim that 'the TRIPS Agreement contains sufficient flexibilities to prevent negative effects of patents' . 22 Article 31 TRIPs permits 'other use of the subject matter of a patent without the authorisation of the right holder, including use by the government or third parties authorised by the government' provided certain criteria are satisfied. To issue a licence, a state must provide adequate remuneration to the respective right holder; attempt to negotiate a voluntary licence with the right holder prior, although this is not required in the event of 'a national emergency or other circumstance of extreme urgency'; use the patent solely for the purpose of its authorization; authorize the licence 'predominantly for 30 This applies to both Article 31 and Article 31bis. This issue is exacerbated because compulsory licences must be issued country-per-country, vaccine-for-vaccine basis: countries cannot issue one compulsory licence covering all vaccines. 31 For COVID-19 vaccines using messenger RNA (mRNA) technology, they would also have to go through a web of patents held and licensed by different stakeholders, including various universities and companies, and license accordingly. 32 Trade agreements further complicate this process as these agreements can restrict the grounds in which developing countries may use TRIPs flexibilities. 33 US free trade agreement (FTAs) with Chile, Morocco, Bahrain and the signatories of the Central American-Dominican Republic FTA, that is Guatemala, El Salvador, Honduras, Costa Rica, Nicaragua and the Dominican Republic, require rightholders to either consent to or be notified of a compulsory licence before it may take effect. 34 This is much more time-consuming than a blanket waiver for all IPRs on every COVID-19 vaccine. Furthermore, with several developing countries lacking domestic manufacturing capacity, they would have to rely on an import/export licence under Article 31bis. 35 To use Article 31bis, countries must first submit a notification to the WTO secretariat. The importing country must notify of its intent to issue a compulsory licence, with information of the product's name and the quantities to be imported, and enforce measures to prevent re-exportation. 36 The exporting country must likewise inform of its intent to grant a compulsory licence, with information specifying the product, export quantities and the final destination, whereby the products must display distinct features signalling that they are produced under the licence, and post this information on a website. 37 As with regular compulsory licences, the grounds for issuing licences remain at the discretion of states themselves, so additional national criteria may apply. For example, Indian patent law requires applicants to identify health problems in the importing country, 38 and the Canadian Patent Act specifies which medicines qualify for Article 31bis usage and imposes a 2-year time limit. 39 These requirements encumbered the process when India and Canada attempted to utilize Article 31bis. Article 31bis has only been used successfully once with the Canada-Rwanda licence, whereas the India-Nepal attempt failed. 40 In the case of the latter, Natco, an Indian generic company, withdrew its application to export 30 000 tablets of Tarceva, a cancer drug originally produced by Roche, from India to Nepal, citing a 'too cumbersome' process as the reason, 41 inter alia because the Indian Patent Office allowed Roche and Pfizer to attend the hearing of the licence between Natco and the Patent Office. 42 The Canada-Rwanda licence, albeit executed, experienced limited success. It involved a strenuous 4-year process and assistance from several nongovernmental organizations. As TriAvar constituted a new fixed-dose combination drug, the Canadian Patent Act did not list it as a drug eligible for a licence. 43 notification only after the Clinton Health Access Initiative intervened. 46 Parties to the licence thus reported of procedural inefficiencies, describing the process as complicated, lengthy and with too few incentives to repeat. 47 Elie Betito, the director of public affairs of Apotex, the Canadian company that exported the drugs to Rwanda, stated that 'it took us more than four years us to get to this point. It's a huge process, with huge costs involved…we will not be doing this again' . 48 In another press release, Apotex shared that 'the delay between approval by Health Canada and issuance of the compulsory license highlights the problems with the process as it exists. It is unnecessarily complex and does not adequately represent the interests of those who require treatment' . 49 MSF similarly labelled the arrangement 'unworkable' . 50 These concerns are not just due to IP. Administrative hurdles, procurement decisions, bureaucracy, regulatory review of the medicine 51 and the Canadian law including additional requirements not mentioned in TRIPs all slowed down the process. 52 Importantly, these concerns are not limited to this licence. The 2016 Report of the United Nations High-Level Panel on Access to Medicines found that Article 31bis fails to represent an effective solution and needs revising. 53 on Tariffs and Trade (GATT), 61 which regulates RTAs. 62 Six African RTAs qualify. 63 Such a pooling arrangement would allow countries to export products imported under Article 31bis to other countries in need and 'form a de facto regional compulsory license' , provided each country issues a licence and the countries share the same health problem. 64 Countries not party to an African RTA may also partake in the scheme, as an RTA country may issue a licence encompassing the medical demand for all the countries involved and the exporting party would supply correspondingly. 65 This arrangement is yet to be tested, and for it to operate, several countries would have to coordinate, and different socio-economic, cultural and political variables align. As the national procedures to issue licensees vary for each state, granting multiple ones simultaneously may encounter difficulties. Many African countries have also not accepted the Article 31bis amendment, 66 and it is unclear whether these countries will during the pandemic. Even if they did, it would still not circumvent the administrative issues listed above (if anything, it would require more administration), nor assuage the political and economic pressures developing countries encounter from developed countries while attempting to grant compulsory licences. Communications published in June 2017 from Brazil, China, Fiji, India and South Africa confirm that this pressure is a reason why many states do not use TRIPs flexibilities. 67 When developing countries have attempted to utilize compulsory licences in the past, many encountered international pressure from developed countries and companies or trade-related repercussions. 68 In addition to these difficulties, compulsory licences are too narrow in scope to increase the production of COVID-19 vaccines on their own without a waiver. A significant benefit of the waiver compared to compulsory licencing is that the waiver concerns all IP, while compulsory licences only apply to patents, which is problematic. As Contreras notes, 'vaccines are complex and volatile products, so patents alone are generally not sufficient to enable a manufacturer to reproduce another company's products' , while a waiver could enable countries to use 'suspend trade secret protection' without violating TRIPs and 'incurring international trade sanctions' . 75 could achieve the same result as a waiver exist but are not used. The WHO 'COVID-19 Technology Access Pool' allows companies to voluntarily share their IPRs, technology transfers and know-how relevant to drugs, vaccines and diagnostic developments in said Pool, which will then be available for free or licensed. 76 None of the vaccine producers have shared their IP via the Pool, meaning it is as of now not a feasible option to improve access. The Open Covid Pledge has also been signed by a large range of companies such as IBM, Facebook and Fujitsu, 77 as well as institutions, committing to 'making all of their patents freely available to the public for use in the fight against COVID-19' . 78 However, pharmaceutical companies producing vaccines have yet to make a pledge. This is where the waiver can help. Because voluntary mechanisms are not being utilized, the waiver can incentivize pharmaceutical companies to make use of these initiatives, saving countries from issuing individual compulsory licences. Or, if countries choose to issue compulsory licences, the waiver can give countries the political and international support needed should they encounter any legal, political or trade consequences. More importantly, if adopted, the waiver can enable more IP to be shared and allow developing countries to produce their own vaccines, saving countries from relying on pharmaceutical companies and other countries, provided three additional factors fall into place. In terms of practical effect, opponents argue that the main issue with the proposed waiver is that it fails to address three significant issues. 79 First, pharmaceutical companies would still have to share vital technology and data in order for new companies to manufacture the vaccines safely, necessitating a type of technology transfer and disclosure of confidential clinical trial data. 80 in June 2020, and the companies intend to manufacture the first batches of mRNA-1273 at Lonza U.S. in July 2020' . 87 In September, 'large-scale production' had begun in the USA. 88 In November 2020, it was further reported that Lonza is 'building out capacity for 400 million doses a year -300 million from three production lines in Visp, Switzerland and 100 million in New Hampshire' . 89 If it is possible to complete technology transfers and repurpose factories in Europe and the USA, why should it not be possible to do the same elsewhere? Companies have transferred vaccine technology to developing countries previously. Fisher, Okediji and Sampath find that 'in the late 1990s, the technology underlying the recombinant Hepatitis B vaccine was transferred to the Republic of Korea, India and Brazil' , resulting in a 'sharp drop' in price. 90 Transferring mRNA technology is admittedly more difficult given its complexities. To tackle this and to scale up vaccine manufacturing in developing countries, the WHO has announced that they are seeking to create a tech transfer hub that will use a 'hub and spoke model … to transfer comprehensive technology package and provide appropriate training to interested manufacturers in low-and middleincome countries' , including mRNA technology, which the Pfizer and Moderna vaccines use. 91 Vaccine technology may also be licensed through the Medicines Patent Pool, that announced on 27 May 2021 that it will increase its mandate to include technology licensing 'with an initial focus on Covid-19 vaccines' . 92 The issue is therefore not the actual transfer of technology but motivating companies to transfer. A waiver may help in this regard as the backing of a legally adopted waiver and support of developed countries can give developing countries greater bargaining power during negotiations with pharmaceutical companies in order to compel IP and tech-sharing. Certain pharmaceutical companies have signed bilateral licences that facilitate tech transfers with manufacturers in developing countries. The Serum Institute of India produces Covishield under a bilateral licence with AstraZeneca, enabling local production, but India suspended vaccine exports headed to developing countries during its own crisis and 'may not export again until the end of this year' . 93 Pfizer/BioNTech announced, on 21 July 2021, that it had signed a letter of intent with Biovac, a South African biotechnology company, to manufacture its mRNA vaccine for distribution within the African Union. 94 However, production will not start before 2022 and the factory will, at full capacity, only produce 100 million finished dosages annually. 95 South Korea is allegedly negotiating whether it may produce mRNA vaccines with Pfizer and Moderna as it has the local capacity to produce '1 billion doses immediately' but how far these talks are and if a deal will be struck remains unclear. 96 Although such agreements are, if executed, a step in the right direction, they are insufficient in terms of aligning supply with global demand. Scaling up production remains an issue. Indeed, pharmaceutical companies claim that production is 'to blame for vaccine under-supply' , as well as 'high-quality standards' and not IP. 97 While it is true that IP is not the only issue for under-supply, it is also true that if the IP and technology was shared, then additional manufacturers could help with production, as factories around the world have publicly shared that they wish to do yet are unable to. 98 100 Moreover, that 'if it [Biolyse] had gotten the green light a year ago, it would have taken the company six months to be up and ready to produce vaccines -and now would be halfway through a year's production' . 101 Kapczynski notes that BioNTech used only 6 months 'to turn a cancer antibody factory into a mRNA factory, complete with regulatory approval' . 102 Repurposing medical factories could potentially curb the production of other essential vaccines and medicines. 103 However, as above with Moderna and Lanzo, it is possible to build new capacity, or, one can, as Moderna did, repurpose an old Polaroid/camera factory to manufacture vaccines. 104 Building new capacity or repurposing non-medical factories is not necessary seeing as several factories wishing to produce vaccines claim that they have available capacity. Relying on reputable, established manufacturers, who already produce many of the world's medicines, also assuages concerns over quality control and vaccine safety, which has been used as a justification for limiting licencing deals and production in developing countries. 105 Bangladesh's Incepta chairman and managing director, Abdul Muktadir, stated that 'Incepta can manufacture bulk antigen for coronavirus vaccines using almost all of its technology platforms' , including mRNA products if the antigen was provided. 106 If it was, then 'production can start immediately as Incepta has several lines sitting idle' wherein Incepta could likely fill 'vials for about 500 million doses a year' with just one line. 107 Kim Soo-jin, senior vice-president of Hanmi Pharmaceuticals, a South Korean pharmaceutical company, shares that they have 'a fully ready, GMP, state-of-the-art facility available' because a clinical trial with Sanofi was discontinued last year. 108 Using medical factories is the preferable option as it is likely cheaper than building new or repurposing nonmedical facilities, although this too comes at an expense, raising the question: where will the money come from? Philanthropy represents one option. Patrick Soon-Shiong, owner of LA Times, recently committed to donating $213 million to help South Africa with tech transfers for COVID-19 vaccines and other products. 109 Another is obtaining financing via the World Bank, who approved an 'an envelope of $12 billion for developing countries to finance the purchase and distribution of COVID-19 vaccines, tests, and treatments for their citizens' , including financing and technical support so that said countries may prepare to deploy vaccines at scale. 110 The World Bank recently increased this funding to $20 billion and, alongside three governments, are investing in a manufacturer based in South Africa to 'boost production of Covid-19 vaccines on the African continent' . 111 Said funding includes financing for the entire vaccine production supply chain. 112 Private-public partnership is another route. Recipharm, global contract development and manufacturing organization, announced in July of 2021 that they have signed a Memorandum of Understanding, with the Moroccan government and a 'consortium of the country's leading banks' , both of which have pledged $500 million in funding, in order to build a 'fillfinish factory' in Morocco by 2023 in order to produce biologics and vaccines for the African continent and 'help it gain vaccine sovereignty and access to future biotherapeutics' . 113 The plant will 'mirror' the one Recipharma oversees in France, which is notably used to produce Moderna's mRNA vaccine. 114 Whether the factory will be used for COVID-19 vaccines remains unclear. Although it could, waiting until 2023 is too long, meaning the above factories, which may start production immediately, are the best option. Despite a waiver, it might be difficult to produce vaccines in developing countries as certain countries restrict the exportation of the raw materials used for vaccines. The USA is using its 'march in' rights under the US Defence Act to ensure that companies prioritize US procurement orders first, which has impacted India's vaccine production as they are short of raw materials, 115 although the USA now exports to India again. 116 Such restrictions would have to be lifted for all countries for the waiver to have effect, particularly as scaling up vaccine production requires additional raw materials. Those used to produce mRNA vaccines, such as lipid nanoparticles, which are also difficult to manufacture. 117 There are already shortages. Vaccine production may therefore only be scaled up if the production of raw materials is too. However, the waiver is not limited to vaccines, so it may encompass the raw materials needed to produce vaccines, enabling additional manufacturers to produce raw materials. 118 Moreover, 'several world-leading groups working on creating better lipid nanoparticles for the delivery of mRNA' . 119 Director general for the global vaccine hub committee under South Korea's health ministry, Lee Kang-ho, discloses that South Korean producers are 'capable of manufacturing and developing such raw materials to help vaccine makers… and the South Korean government is committed to provide all necessary support including financial and administrative aid' . 120 The raw materials needed to produce vaccines may therefore be more available by the time production starts. 121 After the tech is transferred and production is set up, the other manufacturers would still require regulatory approval to market their vaccine. Unless originator companies share their clinical trial data, said manufacturers might struggle to show that their generic vaccine is similar enough to the original without conducting their own clinical trials. 122 As clinical trials are costly and lengthy, relying on this data is vital. There are a few options to consider. Any trade secrets not included in the waiver could be forcibly disclosed under national law, but this might meet jurisdiction issues as many pharmaceutical companies do not have a presence in developing countries. If forcible disclosure is sought in developed countries, such as the EU, wherein Article (1)(2) of the EU Trade Secrets Directive 123 permits trade secret disclosures on public interest grounds, this would require some multijurisdictional data transfer, which would likely take much time, met much resistance given the EU's opposition to the waiver and encounter difficulties, particularly in relation to EU data protection laws. Alternatively, countries could enact domestic legislation to enable information sharing between regional/national medicine agencies 124 or with the WHO, which simplified the standard regulatory pathway for vaccine approval when it introduced 'Emergency Use Listing' , which 'opens the door for countries to expedite their own regulatory approval processes to import and administer vaccines' . 125 Another option is issuing compulsory licences on top com/the-world-is-hungry-for-mrna-covid-vaccines-like-pfizers-butwere-short-of-vital-components-159143 (accessed 2 June 2021). 120 Cha (n 96). 121 Vaccine production is also scaling up in Europe despite alleged raw material shortages. of the waiver. Contreras suggests that a country making use of the waiver 'could also, presumably mandate that foreign companies disclose their proprietary manufacturing and testing information to local producers under a compulsory license' . 126 However, compulsory licences may run into issues in this regard if the country is a signatory to an international agreement containing TRIPs-plus provisions that require data to be protected extensively. For instance, Article 18.50 of the TTP 'requires that, when a party requires approval of a new pharmaceutical product, undisclosed test or other data related to safety and efficacy cannot be used in another party for at least five years from the marketing approval date in the first party' . 127 This strengthens the case of a waiver on data exclusivities, which is indeed the best alternative, accompanied by, for example, the WHO regulatory approval mechanism to expedite the review basis. This background shows that competing pharmaceutical companies and/or generic companies may help if know-how is shared and pre-existing factories are used. Equally, if there are no current factories, then it is vital we invest in repurposing old or creating new factories to speed up production. Despite the alternative methods to circumvent IPRs highlighted above, a global IP waiver would help in this regard. This is because no investor or company will invest in repurposing old factories unless they actually have the rights to produce the vaccine. The waiver may likewise give countries the legal basis needed in order to successfully negotiate technology transfers with pharmaceutical companies, which have thus far proved unsuccessful. Conversely, Hilty et al. claim that 'waiving IP rights may have detrimental consequences for the firms' willingness to cooperate' . 128 This is incorrect for two reasons. First, it assumes that firms are willing to cooperate, which is not per se the case. Certain pharmaceutical companies reportedly rejected offers from other companies in Canada, Bangladesh, Israel and Denmark to help manufacture vaccines in May 2021. 129 Equally, when cooperation has occurred, it has predominantly taken place in high-income countries, while developing countries' calls for cooperation have been met with silence or rejection. Second, threatening to circumvent IPRs has in pre-pandemic times, as well as during, proved to be a powerful way to incentivize voluntary action. 130 GlaxoSmithKline and Boehringer Ingelheim granted a voluntary licence after Cosmos, a local manufacturer, applied for a compulsory licence for a HIV/AIDS drug in Kenya. 131 Abbvie waived its patent rights after Israel issued a compulsory licence for its drug, which was thought to be effective for treating COVID-19. 132 A waiver may similarly spark greater voluntarily cooperation. 133 As the New York Times reports: 'the Europeans are banking on the notion that the vaccine makers, fearing patent waivers, will eventually agree to the transfers, especially if the world's richest countries throw money their way to make sharing know-how more palatable' . 134 Pharmaceutical companies remain opposed to the IP waiver, claiming it will hurt innovation in the short and long run, well beyond this pandemic, by removing incentives to develop essential pharmaceutical products. 135 Academics, such as Mercurio 136 and Hilty et al., 137 support such claims. This strikes at the heart of IP law, which is built on the presumption that awarding temporary monopolies so companies can charge uncompetitive prices to recoup R&D costs provides an incentive to innovate. This in turn ensures that the innovation cycle continues and new inventions are shared with society, creating a richer quality of life for all. However, the innovation process behind the COVID-19 vaccines departs from the norm. The vaccines developed by Pfizer, Moderna, Johnson&Johnson and AstraZeneca all benefitted from unprecedented amounts of public funding throughout their development cycle with the public sector taking much of the financial risk usually involved in pharmaceutical development. A recent article in the Lancet shares that each received the following estimates: (i) AstraZeneca, 138 $1.7 billion in total from CEPI, as well as the US and UK governments; (ii) Johnson&Johnson, $1.5 billion from the US government; (iii) Moderna, $957 million from CEPI, Dolly Parton COVID-19 Research Fund and US government, and (iv) BioNTech with Pfizer, $445 million from the German government. 139 Pfizer is also predicted to reach $33.5 billion in sales in 2021, 140 'with a profit margin percentage of revenue in the high 20s' . 141 Against this background, it is questionable how innovation will be harmed by requesting that publicly funded research be widely available to developing countries during a pandemic, especially after pharmaceutical companies have had much time and many offers to do so voluntarily. Equally questionable is how 'innovation' , which is meant to benefit society, is beneficial if the innovations themselves remain out of reach to those who need them the most. Thanks to international collaboration, public funding and science, pharmaceutical companies have, with the help of governments, universities, and biotechnology companies, developed vaccines in record time. There is finally some light at the end of the tunnel. For some of us. The Economist's Intelligence Unit estimates that vaccines will be widely available in developed countries between September 2021 and March 2022. 142 The same is not estimated to occur for many developing countriesincluding most African countries-until April 2022 or 2023. 143 As of late April 2021, Dr Tedros stated that only 0.3 per cent of the vaccines thus far been administered to Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna's Vaccine (mRNA-1273) Against Novel Coronavirus' Press Release Lonza Aims to Make Ingredients for 400 Million Doses of Moderna's COVID Vaccine Annually' Reuters Moderna Vaccine Production Is Gearing Up Establishment of a COVID-19 mRNA Vaccine Technology Transfer hub to Scale up Global Manufacturing The Medicines Patent Pool Responds to Access Needs for COVID-19 Vaccine Technologies in Low-and Middle-Income Countries' News Factory Owners Around the World Stand Ready to Manufacture Vaccines' The Intercept How to Vaccinate the World, Part 1' LPE Project Scaling up Covid-19 Vaccine Production: What are the Problems and Implications?' The British Medical Journal Opinion How Moderna Plans to Mass-Produce Its Coronavirus Vaccine' Business Insider Covid: Rich States "Block" Vaccine Plans for Developing Nations Times Owner Pledges $213 Million for COVID-19 South Africa' LA Times World Bank Approves $12 Billion for COVID-19 Vaccines World Bank to Finance Vaccine Production in Africa Recipharm signs Memorandum of Understanding (MOU) for the Fill Finish of Vaccines and Biotherapeutics in Morocco With $500 M in local pledges, Recipharm Plans Moroccan Factory to help Africa secure 'Vaccine Sovereignty" Fierce Pharma Is there a ban on Covid Vaccine Exports in the US? to Send Virus-Ravaged India Materials for Vaccines' NY Times Compulsory licence and Crown use Provisions in the Covid-19 Pandemic-the Australian Perspective The authors also note that patent thickets exist for raw materials so supply chain issued may be partly attributable to IP here too The World is Hungry for mRNA COVID Vaccines Like Pfizer's. But we're Short of Vital Components' The Conversation Improving Access to HIV/AIDS Medicines in Africa: Trade-Related Aspects of Intellectual Property rights (TRIPS) Flexibilities Utilization AbbVie Drops Patent Rights for Kaletra Antiviral Treatment What Would It Take to Vaccinate the World Against Covid Pfizer Chief Warns of "Scramble" for raw Materials if Vaccine Patents Waived' Financial Times For AstraZeneca Data, see also Michael Safi Challenges in Ensuring Global Access to COVID-19 Vaccines: Production, Affordability, Allocation, and Deployment' (2021) 397 The Lancet 1023 Pfizer Raises Sales Forecast for Covid Vaccine by Almost a Third to $33bn Jayati Ghosh and Els Torreele on Waiving Covid Patents' The Economist by Invitation The EIU's Latest Vaccine Rollout Forecasts' The Economist the citizens living in developing countries. 144 With countries such as India reporting of record-breaking deaths per day, and with Nepal expected soon to follow, it is imperative that citizens living in developing countries can access the treatments they need to survive.While it is true that IP is not the only factor curbing access to COVID-19 vaccines-political nationalism, export bans and production capabilities remain huge issues-it is also true that IP plays a role. Not only does IP mean exclusive production rights, but it means that a couple of commercial pharmaceutical companies effectively decide where to produce vaccines and who to sell them to. In May 2021, it was reported that the pharmaceutical companies producing COVID-19 vaccines rejected offers from companies in Canada, Bangladesh, Israel and Denmark to help. 145 This begs the question: is insufficient production capacity a fact, or a choice?Although a global waiver of IP for COVID-19 products will not guarantee equal accessibility, it constitutes an important stepping stone towards greater access as it lays the foundation blocks for IPRs to be shared. Indeed, in an interview with Nature, Kiat Ruxrungtham, an immunologist who has, alongside his team, developed another mRNA COVID-19 vaccine that is about to enter human trials, shares that the waiver 'would allow us to use technologies that are currently unaffordable or inaccessible to us to make our vaccine even better 144 WHO (n 1). 145 Furlong (n 97). and cheaper' . 146 It may attract the investments needed to repurpose old or build new factories to produce more vaccines.Moreover, it legitimizes the struggles that developing countries are facing and will continue to face when it comes to securing COVID-19 vaccines wherein developed countries are partly to blame. As Woulters et al. observe, 'scarcity in supply coupled with the large volumes of pre-orders made by richer countries creates challenges to achieving timely, universal access' . 147 This is made worse when developed countries are now administering booster shots that will 'use up roughly 440 million doses of the global supply' , 148 and when countries such as Canada take vaccines destined for developing countries through COVAX. It is not right that developed countries purchased enough vaccines to vaccinate their own citizens multiple times over before developing countries could even secure one dosage, take donated vaccines for themselves and stand in the way of developing countries producing their own vaccines. Something has to give. And that must be developed countries blocking the waiver. Additional issues must indeed be overcome for the waiver to take effect, and further research is needed, particularly when it comes to increasing the production of raw materials. But it is vital that countries and researchers be part of the solution, not the problem.